Navigation Links
Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - Pfizer announced today that Lipitor (atorvastatin calcium) Tablets 80 mg reduced the risk of stroke, coronary heart disease events and major coronary events in type 2 diabetes patients who had no known coronary heart disease but who had experienced a recent stroke or mini-stroke, compared with placebo. The results are from a new analysis of the landmark Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, and were presented at the 67th Annual Scientific Sessions of the American Diabetes Association.

According to the National Institute of Diabetes and Digestive and Kidney Diseases, the risk for stroke is two to four times higher among people with diabetes, and heart disease and stroke account for nearly two-thirds of deaths in people with diabetes.

"People with type 2 diabetes who have had a stroke are at a much higher risk of having a second stroke, a coronary heart disease event or revascularization procedure than people without type 2 diabetes," said Dr. Michael Welch, lead SPARCL investigator, neurologist and president of Rosalind Franklin University of Medicine & Science. "In this analysis of patients with type 2 diabetes with no known coronary heart disease, we found Lipitor to be effective in reducing these risks."

In this pre-specified analysis (n=794), Lipitor reduced the risk of stroke by 30 percent, and coronary heart disease events and major coronary events by 51 percent, compared with placebo. Coronary heart disease events include cardiac death, heart attack, resuscitated cardiac arrest, unstable chest pain, revascularization, or chest pain requiring emergency hospitalization. Major coronary events include cardiac death, heart attack, or resuscitated cardiac arrest.

An additional analysis evaluated 781 patients in the SPARCL trial who were classified as having metabolic syndrome and who had a recent stroke o
'"/>




Page: 1 2 3

Related medicine technology :

1. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
2. Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients
3. Two New Imaging Studies Show Higher Dose Lipitor Stopped the Progression of Atherosclerosis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
6. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
9. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
Post Your Comments:
(Date:7/28/2014)...  Luminex Corporation (NASDAQ: LMNX ) today ... 30, 2014. Financial and operating highlights include the following: ... million, a 2 percent increase over the second quarter ... $8.3 million, a 9 percent increase over the second ... 268 multiplexing analyzers, which included 148 LX systems, 96 ...
(Date:7/28/2014)...  MiMedx Group, Inc. (NASDAQ: MDXG ), an integrated ... bioimplants processed from human amniotic membrane, announced today its results ... include: , Revenue exceeds upper end of ... million , Quarter-over-quarter revenue grew by ... 181% over Q2 2013 and 40% sequentially over Q1 2014 ...
(Date:7/28/2014)... 2014 Reportbuyer.com has added a new market ... 2014-2018 https://www.reportbuyer.com/product/2225723/Global-Bone-Densitometers-Market-2014-2018.html ... a special type of X-ray test used to measure ... primarily to detect osteopenia or osteoporosis, diseases in which ... fractures is high. The purpose of bone densitometry is ...
Breaking Medicine Technology:Luminex Corporation Reports Second Quarter 2014 results 2Luminex Corporation Reports Second Quarter 2014 results 3Luminex Corporation Reports Second Quarter 2014 results 4Luminex Corporation Reports Second Quarter 2014 results 5Luminex Corporation Reports Second Quarter 2014 results 6Luminex Corporation Reports Second Quarter 2014 results 7Luminex Corporation Reports Second Quarter 2014 results 8Luminex Corporation Reports Second Quarter 2014 results 9Luminex Corporation Reports Second Quarter 2014 results 10Luminex Corporation Reports Second Quarter 2014 results 11Luminex Corporation Reports Second Quarter 2014 results 12Luminex Corporation Reports Second Quarter 2014 results 13Luminex Corporation Reports Second Quarter 2014 results 14Luminex Corporation Reports Second Quarter 2014 results 15Luminex Corporation Reports Second Quarter 2014 results 16Luminex Corporation Reports Second Quarter 2014 results 17MiMedx Announces Record Second Quarter Results 2MiMedx Announces Record Second Quarter Results 3MiMedx Announces Record Second Quarter Results 4MiMedx Announces Record Second Quarter Results 5MiMedx Announces Record Second Quarter Results 6MiMedx Announces Record Second Quarter Results 7MiMedx Announces Record Second Quarter Results 8MiMedx Announces Record Second Quarter Results 9MiMedx Announces Record Second Quarter Results 10MiMedx Announces Record Second Quarter Results 11MiMedx Announces Record Second Quarter Results 12MiMedx Announces Record Second Quarter Results 13MiMedx Announces Record Second Quarter Results 14MiMedx Announces Record Second Quarter Results 15MiMedx Announces Record Second Quarter Results 16MiMedx Announces Record Second Quarter Results 17MiMedx Announces Record Second Quarter Results 18Global Bone Densitometers Market 2014-2018 2Global Bone Densitometers Market 2014-2018 3
... and Only Approved Platelet Producer in Europe Represents ... Switzerland, Feb. 6 Amgen (Nasdaq: ... (EC) has granted marketing authorisation for Nplate(R) (romiplostim) ... (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory ...
... CAMBRIDGE, Mass. and LONDON, Feb. 6 Idenix Pharmaceuticals, ... today announced the execution of a license agreement granting ... a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) in Phase ... treatment of HIV/AIDS. New NNRTIs are needed to ...
Cached Medicine Technology:Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 2Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 3Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 5Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 6Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 7Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 8Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV 2Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV 3Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV 4Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV 5
(Date:7/28/2014)... Ticket Down is reliable source ... Dallas, TX at the Cotton Bowl. The 2014 Guinness ... and it is an eight team tourney. The tournament ... teams from La Liga, Serie A, English Premier League, and ... out on the pitch include: Manchester United, Manchester City, ...
(Date:7/28/2014)... York, NY (PRWEB) July 28, 2014 ... filed on behalf of individuals who were allegedly ... Replacement System continue to move forward in U.S. District ... According to an Order issued on July 18, 2014, ... a motion filed by the Plaintiffs’ Steering Committee that ...
(Date:7/28/2014)... July 28, 2014 Shofner Vision ... Military June . Renowned LASIK and Cataract Surgeon, ... provide significant funds and public awareness for local ... military personnel and their families. “This was our ... give nearly $5,000 to a variety of local ...
(Date:7/28/2014)... 2014 Glutamine is the most abundant ... to be conditionally essential during times when the body ... recovery & Immune System Support. , Having a heavy ... produces, supplementing with additional glutamine may be advantageous. Glutamine ... the body, digestion and immune system function. Stress on ...
(Date:7/28/2014)... Cape Regional Medical Center, is currently ... solution in an effort to streamline its bi-directional ... their New Jersey health information exchange (NJSHINE). , ... New Jersey, serves the local population and more ... inpatient and outpatient services. With a strong commitment ...
Breaking Medicine News(10 mins):Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 2Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 3Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3
... dating has not only shed its stigma, it has ... other than meeting through friends, according to a new ... The digital revolution in romance is a boon ... potential partners, reports the team of psychological scientists who ...
... , FRIDAY, Feb. 3 (HealthDay News) -- ,Extended synaptic development ... new study suggests. During the first few years of ... information and experiences from the environment in a way that ... This is due to extended synaptic development, according to the ...
... been mapped with unprecedented accuracy in the bloodstream of ... brand new approach, in an attempt to assess and ... through the body, and solve the problem of predicting ... to a previous generation of systems, the researchers state ...
... aged 70 and over will increase by 40% in ... over will more than double1. Health authorities and the ... of people suffering costly and debilitating age-related chronic diseases ... dementia. The significant increase in the numbers of people ...
... (February 1, 2012) Rates of diabetes vary widely across ... by Dr. Longjian Liu of Drexel University,s School of ... diabetes now live in developing countries. Liu,s study found ... in developing countries, and that one in 10 diagnosed ...
... , THURSDAY, Feb. 2 (HealthDay News) -- Sometimes, there,s nothing ... that where the itch resides is key to ... understanding of itch and might even help folks battling itchy ... professor of dermatology at Wake Forest Baptist Medical Center in ...
Cached Medicine News:Health News:Online dating research shows cupid's arrow is turning digital 2Health News:Online dating research shows cupid's arrow is turning digital 3Health News:Why Human Brains Are Smarter Than Chimp Brains 2Health News:New technology to tackle treatment-resistant cancers 2Health News:New study to assess 3 simple, cost-effective strategies to promote healthy aging 2Health News:Diabetes rates vary widely in developing countries, 1 in 10 cases untreated 2Health News:Pleasure in Scratching an Itch May Depend on Location 2
... cervical stabilization from neutral to ... widening under occiput when collar ... fasterner.,Exo-Static™ Collar with Chin Piece ... neutral position and restricts lateral ...
... Padding&trade is perfect for use for lightweight ... materials or used to line braces, prosthetics, ... against shock and vibration and conforms to ... and chaffing. It is a 2mm thick ...
... support and stabilization for muscles and ligaments ... pain and discomfort. Strong elastic abdominal ... for varying degrees of compression. Two ... for extra-firm support. Tapered in front ...
... Designed with patient need and comfort ... Appliance) family of products effectively address ... The Chairback frame attachment provides optimal ... (LSO) provides superior support for patient ...
Medicine Products: